Search Results - "Žucenka, Andrius"

A Case of Successful Allogeneic Hematopoietic Stem Cell Transplantation in a Severely Underweight Patient with Aplastic Anemia by Banceviča, Lilija, Žučenka, Andrius

“…Allogeneic hematopoietic stem cell transplantation (alloHSTC) is considered definitive and the most effective treatment for young patients diagnosed with…”
Get full text

Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement by Dapkevičiūtė-Purlienė, Austėja, Augustinavičius, Vytautas, Žučenka, Andrius

“…Extranodal natural killer/T-cell lymphoma (ENKL) is a rare subtype of mature T and natural killer cell lymphomas associated with Epstein-Barr virus. A…”
Get full text

Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation by Zucenka, Andrius, Vaitekenaite, Vilmante, Maneikis, Kazimieras, Davainis, Linas, Pileckyte, Regina, Trociukas, Igoris, Peceliunas, Valdas, Zvirblis, Tadas, Staras, Vytautas, Griskevicius, Laimonas

“…We retrospectively compared the outcomes of 20 patients receiving Venetoclax + low-dose Cytarabine + Actinomycin D (ACTIVE) with 29 patients receiving FLAG-Ida…”
Get full text

Oxidative phosphorylation inhibition induces anticancerous changes in therapy‐resistant–acute myeloid leukemia patient cells by Vitkevičienė, Aida, Janulis, Vytautas, Žučenka, Andrius, Borutinskaitė, Veronika, Kaupinis, Algirdas, Valius, Mindaugas, Griškevičius, Laimonas, Navakauskienė, Rūta

“…Treatment of acute myeloid leukemia (AML) is still a challenge because of common relapses or resistance to treatment. Therefore, the development of new…”
Get full text

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation by Čepulytė, Rūta, Pečeliūnas, Valdas, Žučenka, Andrius

“…Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic…”
Get full text

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients by Zucenka, Andrius, Maneikis, Kazimieras, Pugaciute, Birute, Ringeleviciute, Ugne, Dapkeviciute, Austeja, Davainis, Linas, Daukelaite, Guoda, Burzdikaite, Paulina, Staras, Vytautas, Griskevicius, Laimonas

“…We retrospectively collected clinical data on 31 relapsed or refractory acute myeloid leukemia (R/R AML) patients who were treated with outpatient glasdegib…”
Get full text

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies by Daraskevicius, Justinas, Petraitis, Vidmantas, Davainis, Linas, Zucenka, Andrius

“…Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell…”
Get full text

Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission by Borutinskaitė, Veronika, Žučenka, Andrius, Vitkevičienė, Aida, Stoškus, Mindaugas, Kaupinis, Algirdas, Valius, Mindaugas, Gineikienė, Eglė, Navakauskienė, Rūta

“…Acute myeloid leukemia (AML) is an aggressive, heterogeneous group of malignancies with different clinical behaviors and different responses to therapy. For…”
Get full text

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA by Žučenka, Andrius, Vasilevska, Dominika, Daukėlaitė, Guoda, Trociukas, Igoris, Pečeliūnas, Valdas, Pileckyte, Regina, Griškevičius, Laimonas

Get full text

Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study by Judickas, Šarūnas, Stasiūnaitis, Raimundas, Žučenka, Andrius, Žvirblis, Tadas, Šerpytis, Mindaugas, Šipylaitė, Jūratė

“…: Oncohematological patients have a high risk of mortality when they need treatment in an intensive care unit (ICU). The aim of our study is to analyze the…”
Get full text

PB2005: AZACITIDINE IN COMBINATION WITH 14‐DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS‐2 IN CLINICAL PRACTICE SETTING by Žučenka, Andrius, Čepulytė, Rūta, Davainienė, Birutė, Vasilevska, Dominika, Pileckyte, Regina, Trociukas, Igoris, Pečeliūnas, Valdas, Griškevičius, Laimonas

Get full text

Venetoclax-Based Therapies for Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2 in Clinical Practice Setting by Žucenka, Andrius, Kevličius, Lukas, Davainis, Linas, Davainienė, Birutė, Maneikis, Kazimieras, Pileckytė, Regina, Vasilevska, Dominika, Trociukas, Igoris, Vaitekėnaitė, Vilmantė, Griškevičius, Laimonas

Get full text

HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia by Navakauskiene, Ruta, Borutinskaitė, Veronika, Gineikienė, Eglė, Stoškus, Mindaugas, Žučenka, Andrius, Skiauterytė, Giedrė, Vitkevičienė, Aida, Griškevičius, Laimonas

“…Acute promyelocytic leukemia (APL) is characterized by PML-RARA translocation, which causes the blockage of promyelocyte differentiation. Conventional…”
Get full text

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts by Shallis, Rory M, Daver, Naval, Altman, Jessica K, Komrokji, Rami S, Pollyea, Daniel A, Badar, Talha, Bewersdorf, Jan P, Bhatt, Vijaya R, de Botton, Stéphane, de la Fuente Burguera, Adolfo, Carraway, Hetty E, Desai, Pinkal, Dillon, Richard, Duployez, Nicolas, El Chaer, Firas, Fathi, Amir T, Freeman, Sylvie D, Gojo, Ivana, Grunwald, Michael R, Jonas, Brian A, Konopleva, Marina, Lin, Tara L, Mannis, Gabriel N, Mascarenhas, John, Michaelis, Laura C, Mims, Alice S, Montesinos, Pau, Pozdnyakova, Olga, Pratz, Keith W, Schuh, Andre C, Sekeres, Mikkael A, Smith, Catherine C, Stahl, Maximilian, Subklewe, Marion, Uy, Geoffrey L, Voso, Maria Teresa, Walter, Roland B, Wang, Eunice S, Zeidner, Joshua F, Žučenka, Andrius, Zeidan, Amer M

“…The existence of two acute myeloid leukaemia classification systems—one put forth by WHO and one by the International Consensus Classification in 2022—is…”
Get full text

P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE by Rubnitz, Jeffrey, C. Issa, Ghayas, M. Stein, Eytan, Shukla, Neerav, Stock, Wendy, Žučenka, Andrius, Khazal, Sajad, Khera, Nandita, Stieglitz, Elliot, Rubinstein, Jeremy, Rosen, Galit, Ghiraldi, Rachel, Van Nguyen, Huy, Mcneer, Nicole, Zwaan, C. Michel

Get full text

Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan by Maneikis, Kazimieras, Ringeleviciute, Ugne, Bacevicius, Justinas, Dieninyte-Misiune, Egle, Burokaite, Emilija, Kazbaraite, Gintare, Monika Janusaite, Marta, Dapkeviciute, Austeja, Zucenka, Andrius, Peceliunas, Valdas, Kryzauskaite, Lina, Kasiulevicius, Vytautas, Ringaitiene, Donata, Zablockiene, Birute, Zvirblis, Tadas, Marinskis, Germanas, Jancoriene, Ligita, Griskevicius, Laimonas

“…To assess cardiac safety in COVID-19 patients treated with the combination of Hydroxychloroquine and Azithromycin using arrhythmia risk management plan. We…”
Get full text

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience by Issa, Ghayas C., Cuglievan, Branko, Stein, Eytan, Arellano, Martha L., Žucenka, Andrius, Khera, Nandita, Stone, Richard M., Thirman, Michael J., DiPersio, John F., Karras, Nicole, Gu, Yu, Bagley, Rebecca G., Rosen, Galit, Tamang, David, Dishman, Kimberly, Scalera, Sushama, Meyers, Michael L., Madigan, Kate, McNeer, Nicole, Aldoss, Ibrahim

Get full text

Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia by Zucenka, Andrius, Griskevicius, Laimonas

“…We have conducted a retrospective, single-centre analysis of 20 patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (FLT3m AML) who…”
Get full text

Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies by Kevlicius, Lukas, Cepulyte, Ruta, Vasilevska, Dominika, Griskevicius, Laimonas, Zucenka, Andrius

Get full text

Real-World Comparison of Venetoclax-Based Treatment Versus Intensive Chemotherapy As Bridging to Allogeneic Stem Cell Transplantation in MDS-IB2 Patients by Zucenka, Andrius, Davainienė, Birutė, Vaitekėnaitė, Vilmantė, Čepulytė, Rūta, Davainis, Linas, Daukėlaitė, Guoda, Kevličius, Lukas, Pileckytė, Regina, Trociukas, Igoris, Griškevičius, Laimonas

“…Background Allogeneic stem cell transplantation (alloSCT) is the cornerstone therapy for myelodysplastic syndromes with increased blasts-2 (MDS-IB2). However,…”
Get full text